IN182468B - - Google Patents

Info

Publication number
IN182468B
IN182468B IN102MA1996A IN182468B IN 182468 B IN182468 B IN 182468B IN 102MA1996 A IN102MA1996 A IN 102MA1996A IN 182468 B IN182468 B IN 182468B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Varlashkin
Richard Augustus Winnike
William Bayne Grubb Iii
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN182468(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IN182468B publication Critical patent/IN182468B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
IN102MA1996 1995-01-20 1996-01-19 IN182468B (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
IN182468B true IN182468B (OSRAM) 1999-04-17

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
IN102MA1996 IN182468B (OSRAM) 1995-01-20 1996-01-19

Country Status (40)

Country Link
US (1) US6107302A (OSRAM)
EP (1) EP0804436B1 (OSRAM)
JP (1) JP3176633B2 (OSRAM)
KR (1) KR100376074B1 (OSRAM)
CN (1) CN1049893C (OSRAM)
AP (1) AP662A (OSRAM)
AR (1) AR002270A1 (OSRAM)
AT (1) ATE302777T1 (OSRAM)
AU (1) AU702794B2 (OSRAM)
BG (1) BG63393B1 (OSRAM)
BR (1) BR9606768A (OSRAM)
CA (1) CA2210799C (OSRAM)
CY (1) CY2531B1 (OSRAM)
CZ (1) CZ297065B6 (OSRAM)
DE (1) DE69635106T2 (OSRAM)
DK (1) DK0804436T3 (OSRAM)
EA (1) EA000364B1 (OSRAM)
EE (1) EE03528B1 (OSRAM)
ES (1) ES2248806T3 (OSRAM)
FI (1) FI973063L (OSRAM)
GB (1) GB9501178D0 (OSRAM)
GE (1) GEP20001940B (OSRAM)
HR (1) HRP960024B1 (OSRAM)
HU (1) HU222993B1 (OSRAM)
IL (1) IL116831A (OSRAM)
IN (1) IN182468B (OSRAM)
IS (1) IS2268B (OSRAM)
NO (1) NO315558B1 (OSRAM)
NZ (1) NZ298851A (OSRAM)
OA (1) OA10499A (OSRAM)
PL (1) PL182175B1 (OSRAM)
RO (1) RO118693B1 (OSRAM)
RS (1) RS49518B (OSRAM)
SI (1) SI0804436T1 (OSRAM)
SK (1) SK285329B6 (OSRAM)
TR (1) TR199700656T1 (OSRAM)
UA (1) UA46001C2 (OSRAM)
UY (1) UY25779A1 (OSRAM)
WO (1) WO1996022291A1 (OSRAM)
ZA (1) ZA96449B (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
ES2210490T3 (es) * 1996-01-19 2004-07-01 Glaxo Group Limited Uso de valaciclovir para la fabricacion de un medicamento para el tratamiento del herpes genital por una unica administracion diaria.
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
KR20000070223A (ko) * 1997-01-17 2000-11-25 에가시라 구니오 신규한 z-발라사이클로비르 결정
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
JP5043286B2 (ja) * 2001-09-07 2012-10-10 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビル塩酸塩の結晶型
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CA2465928C (en) * 2001-11-14 2010-01-19 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP1638972A2 (en) * 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
KR20060117355A (ko) * 2004-01-21 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로버 염산염의 제조 방법
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
WO2006127217A2 (en) * 2005-05-25 2006-11-30 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
RU2569749C2 (ru) * 2007-08-17 2015-11-27 Бёрингер Ингельхайм Интернациональ Гмбх Производные пурина, предназначенные для применения для лечения заболеваний, связанных с баф (белок-активатор фибробластов)
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) * 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽(常州)药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
DE69426880T2 (de) * 1993-06-10 2001-10-31 Rolabo S.L., Zaragoza Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
JP3176633B2 (ja) 2001-06-18
WO1996022291A1 (en) 1996-07-25
SK285329B6 (sk) 2006-11-03
AP9701058A0 (en) 1997-10-31
KR19980701525A (ko) 1998-05-15
JPH11503718A (ja) 1999-03-30
CA2210799A1 (en) 1996-07-25
PL321326A1 (en) 1997-12-08
YU3396A (sh) 1998-12-23
HRP960024B1 (en) 2005-08-31
KR100376074B1 (ko) 2003-06-02
IS4527A (is) 1997-07-15
HU222993B1 (hu) 2004-01-28
US6107302A (en) 2000-08-22
IL116831A0 (en) 1996-05-14
NO973326L (no) 1997-09-16
SI0804436T1 (sl) 2006-02-28
ES2248806T3 (es) 2006-03-16
GEP20001940B (en) 2000-02-05
RO118693B1 (ro) 2003-09-30
UY25779A1 (es) 2000-08-21
GB9501178D0 (en) 1995-03-08
RS49518B (sr) 2006-10-27
DK0804436T3 (da) 2005-12-27
HRP960024A2 (en) 1997-10-31
DE69635106D1 (de) 2005-09-29
CY2531B1 (en) 2006-04-12
AU4453996A (en) 1996-08-07
AR002270A1 (es) 1998-03-11
CA2210799C (en) 2008-06-10
MX9705462A (es) 1997-10-31
NO973326D0 (no) 1997-07-18
ZA96449B (en) 1996-08-07
BR9606768A (pt) 1997-12-30
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
OA10499A (en) 2002-04-10
CZ229497A3 (en) 1997-12-17
ATE302777T1 (de) 2005-09-15
CZ297065B6 (cs) 2006-08-16
AU702794B2 (en) 1999-03-04
EA199700124A1 (ru) 1997-12-30
BG101833A (bg) 1998-04-30
HUP9801836A2 (hu) 1999-05-28
DE69635106T2 (de) 2006-06-08
PL182175B1 (pl) 2001-11-30
SK96597A3 (en) 1998-02-04
EP0804436B1 (en) 2005-08-24
EP0804436A1 (en) 1997-11-05
AP662A (en) 1998-08-19
FI973063A0 (fi) 1997-07-18
HUP9801836A3 (en) 1999-06-28
IL116831A (en) 1998-10-30
FI973063A7 (fi) 1997-09-18
UA46001C2 (uk) 2002-05-15
TR199700656T1 (xx) 1998-03-21
FI973063L (fi) 1997-09-18
EE9700175A (et) 1998-02-16
EE03528B1 (et) 2001-10-15
EA000364B1 (ru) 1999-06-24
CN1179159A (zh) 1998-04-15
IS2268B (is) 2007-07-15
NO315558B1 (no) 2003-09-22
NZ298851A (en) 1999-01-28

Similar Documents

Publication Publication Date Title
BR122012014331A2 (OSRAM)
BRPI9612258B1 (OSRAM)
BRPI9612138B1 (OSRAM)
CH0741373H1 (OSRAM)
BR7502120U (OSRAM)
BR7501503U (OSRAM)
CN3032332S (OSRAM)
CN3032568S (OSRAM)
CN3035869S (OSRAM)
CN3029801S (OSRAM)
CN3029928S (OSRAM)
CN3030154S (OSRAM)
CN3030197S (OSRAM)
CN3030225S (OSRAM)
CN3030296S (OSRAM)
CN3030415S (OSRAM)
CN3030542S (OSRAM)
CN3030543S (OSRAM)
CN3030760S (OSRAM)
CN3031001S (OSRAM)
CN3031350S (OSRAM)
CN3031655S (OSRAM)
CN3031742S (OSRAM)
CN3031926S (OSRAM)
CN3036647S (OSRAM)